Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Veritas Genetics
company
About
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $12M
- Industries
- Biotechnology,Genetics,Health Care,Personal Health
- Founded date
- Jan 1, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$42M
Veritas Genetics has raised a total of
$42M
in funding over 2 rounds. Their latest funding was raised on
Oct 17, 2016 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 17, 2016 | Series B | $30M | 1 | — | — | Detail |
| Jun 15, 2015 | Series A | $12M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Veritas Genetics is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
